Textination Newsline

Reset
6 results
Wearable Robots for Parkinson’s Disease Image: Tom Claes, unsplash
19.02.2024

Wearable Robots for Parkinson’s Disease

Freezing is one of the most common and debilitating symptoms of Parkinson’s disease, a neurodegenerative disorder that affects more than 9 million people worldwide. When individuals with Parkinson’s disease freeze, they suddenly lose the ability to move their feet, often mid-stride, resulting in a series of staccato stutter steps that get shorter until the person stops altogether. These episodes are one of the biggest contributors to falls among people living with Parkinson’s disease.

Today, freezing is treated with a range of pharmacological, surgical or behavioral therapies, none of which are particularly effective. What if there was a way to stop freezing altogether?

Freezing is one of the most common and debilitating symptoms of Parkinson’s disease, a neurodegenerative disorder that affects more than 9 million people worldwide. When individuals with Parkinson’s disease freeze, they suddenly lose the ability to move their feet, often mid-stride, resulting in a series of staccato stutter steps that get shorter until the person stops altogether. These episodes are one of the biggest contributors to falls among people living with Parkinson’s disease.

Today, freezing is treated with a range of pharmacological, surgical or behavioral therapies, none of which are particularly effective. What if there was a way to stop freezing altogether?

Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and the Boston University Sargent College of Health & Rehabilitation Sciences have used a soft, wearable robot to help a person living with Parkinson’s walk without freezing. The robotic garment, worn around the hips and thighs, gives a gentle push to the hips as the leg swings, helping the patient achieve a longer stride.

The device completely eliminated the participant’s freezing while walking indoors, allowing them to walk faster and further than they could without the garment’s help.

“We found that just a small amount of mechanical assistance from our soft robotic apparel delivered instan-taneous effects and consistently improved walking across a range of conditions for the individual in our study,” said Conor Walsh, the Paul A. Maeder Professor of Engineering and Applied Sciences at SEAS and co-corresponding author of the study.

The research demonstrates the potential of soft robotics to treat this frustrating and potentially dangerous symptom of Parkinson’s disease and could allow people living with the disease to regain not only their mobility but their independence.

For over a decade, Walsh’s Biodesign Lab at SEAS has been developing assistive and rehabilitative robotic technologies to improve mobility for individuals’ post-stroke and those living with ALS or other diseases that impact mobility. Some of that technology, specifically an exosuit for post-stroke gait retraining, received support from the Wyss Institute for Biologically Inspired Engineering, and Harvard’s Office of Technology Development coordinated a license agreement with ReWalk Robotics to commercialize the technology.

In 2022, SEAS and Sargent College received a grant from the Massachusetts Technology Collaborative to support the development and translation of next-generation robotics and wearable technologies. The research is centered at the Move Lab, whose mission is to support advances in human performance enhancement with the collaborative space, funding, R&D infrastructure, and experience necessary to turn promising research into mature technologies that can be translated through collaboration with industry partners. This research emerged from that partnership.

“Leveraging soft wearable robots to prevent freezing of gait in patients with Parkinson’s required a collaboration between engineers, rehabilitation scientists, physical therapists, biomechanists and apparel designers,” said Walsh, whose team collaborated closely with that of Terry Ellis,  Professor and Physical Therapy Department Chair and Director of the Center for Neurorehabilitation at Boston University.

Leveraging soft wearable robots to prevent freezing of gait in patients with Parkinson’s required a collaboration between engineers, rehabilitation scientists, physical therapists, biomechanists and apparel designers.

The team spent six months working with a 73-year-old man with Parkinson’s disease, who — despite using both surgical and pharmacologic treatments — endured substantial and incapacitating freezing episodes more than 10 times a day, causing him to fall frequently. These episodes prevented him from walking around his community and forced him to rely on a scooter to get around outside.

In previous research, Walsh and his team leveraged human-in-the-loop optimization to demonstrate that a soft, wearable device could be used to augment hip flexion and assist in swinging the leg forward to provide an efficient approach to reduce energy expenditure during walking in healthy individuals.

Here, the researchers used the same approach but to address freezing. The wearable device uses cable-driven actuators and sensors worn around the waist and thighs. Using motion data collected by the sensors, algorithms estimate the phase of the gait and generate assistive forces in tandem with muscle movement.

The effect was instantaneous. Without any special training, the patient was able to walk without any freezing indoors and with only occasional episodes outdoors. He was also able to walk and talk without freezing, a rarity without the device.

“Our team was really excited to see the impact of the technology on the participant’s walking,” said Jinsoo Kim, former PhD student at SEAS and co-lead author on the study.

During the study visits, the participant told researchers: “The suit helps me take longer steps and when it is not active, I notice I drag my feet much more. It has really helped me, and I feel it is a positive step forward. It could help me to walk longer and maintain the quality of my life.”

“Our study participants who volunteer their time are real partners,” said Walsh. “Because mobility is difficult, it was a real challenge for this individual to even come into the lab, but we benefited so much from his perspective and feedback.”

The device could also be used to better understand the mechanisms of gait freezing, which is poorly understood.

“Because we don’t really understand freezing, we don’t really know why this approach works so well,” said Ellis. “But this work suggests the potential benefits of a ’bottom-up’ rather than ’top-down’ solution to treating gait freezing. We see that restoring almost-normal biomechanics alters the peripheral dynamics of gait and may influence the central processing of gait control.”

The research was co-authored by Jinsoo Kim, Franchino Porciuncula, Hee Doo Yang, Nicholas Wendel, Teresa Baker and Andrew Chin. Asa Eckert-Erdheim and Dorothy Orzel also contributed to the design of the technology, as well as Ada Huang, and Sarah Sullivan managed the clinical research. It was supported by the National Science Foundation under grant CMMI-1925085; the National Institutes of Health under grant NIH U01 TR002775; and the Massachusetts Technology Collaborative, Collaborative Research and Development Matching Grant.

Source:

The research is published in Nature Medicine.
Source Leah Burrows
Harvard John A. Paulson. School of Engineering and Applied Sciences

Fibroblasts (connective tissue cells) on the electrospun Renacer® membrane under the confocal microscope (red: cytoskeleton of the cells, blue: cell nuclei). (c) Fraunhofer-Institut für Silicatforschung ISC
02.05.2023

Bioresorbable membrane: depot for active substances

Fraunhofer researchers have succeeded in using the bioresorbable silica gel Renacer® to produce an electrospun membrane that is neither cytotoxic to cells nor genotoxic. This model mimics fibrous structures found in connective tissue and is therefore particularly suitable for regenerative applications, such as for improved wound healing.
 
The treatment of large as well as internal wounds is challenging and can be a very lengthy process. Researchers at the Fraunhofer Institute for Silicate Research ISC and the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM have developed a bioresorbable membrane for this use. This membrane supports wound healing and biodegrades completely in the body to a natural substance.

Fraunhofer researchers have succeeded in using the bioresorbable silica gel Renacer® to produce an electrospun membrane that is neither cytotoxic to cells nor genotoxic. This model mimics fibrous structures found in connective tissue and is therefore particularly suitable for regenerative applications, such as for improved wound healing.
 
The treatment of large as well as internal wounds is challenging and can be a very lengthy process. Researchers at the Fraunhofer Institute for Silicate Research ISC and the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM have developed a bioresorbable membrane for this use. This membrane supports wound healing and biodegrades completely in the body to a natural substance.

The basis for the novel membrane is a fiber fleece developed at Fraunhofer ISC. This fleece has already been approved as a medical device to support the regeneration of chronic wounds, such as the diabetic foot. During the healing process, the material dissolves completely within six to eight weeks. Using the electrospinning method, the researchers have now managed to reduce the 50-micrometer fiber diameter by a factor of more than 50, resulting in fibers with diameters of less than one micrometer (µm). This made it possible to spin a silica gel sol into an open-meshed silica gel membrane consisting of fibers with a diameter of about one µm. In some cases, the diameters achieved were as small as 100 nanometers. “These fiber systems imitate the extracellular matrix, the fiber structures found in connective tissue, in the body and are very well tolerated by human cells for tissue regeneration. They cause no foreign body reactions and no internal scarring. The innovative silica gel membrane releases only one degradation product, ortho-silicic acid. This has a regenerative effect on the tissue and promotes the closing of wounds,” explains Dr. Bastian Christ, a scientist at the Fraunhofer ISC in Würzburg. Together with his colleagues, he was in charge of the synthesis and processing of the material.
 
“While the original fiber fleece of 50 µm thick fibers is inserted into a chronic wound from the outside, the thinner fiber fleece is also suitable for internal use. Theoretically, it could be placed onto the filler material used for bone defects in the jaw to accelerate wound healing,” is how Dr. Christina Ziemann, research scientist at Fraunhofer ITEM responsible for the biological evaluation of the material, describes one of numerous possible applications. “In principle, the membrane can be glued in the body with biodegradable adhesives.

Material is neither cyto- nor genotoxic
Using a confocal microscope, a special light microscope, it was possible to show that the small-meshed membrane, which serves as a demonstrator, exhibits a barrier function. This prevents the passage of connective tissue cells for a period of at least seven days without interfering with cell proliferation. In addition, the membrane is resorbable, is not cyto- or genotoxic and thus causes no direct damage to tissue or DNA.

Fiber diameter and mesh size influence the behavior of the cells
A thin fiber diameter of 100 nanometers with thin meshes was chosen for use as an adhesion barrier to prevent postoperative adhesions and scarring. With this configuration, only nutrients could pass through the fiber fleece, but connective tissue cells could not. With a fiber diameter of one micrometer and correspondingly wider meshes, on the other hand, the cells grow into the fiber mesh, proliferate there and have a regenerating effect on the surrounding tissue. “By adjusting the material properties, such as fiber diameter and mesh size, it is possible to influence the behavior of the cells as desired,” says Christ. The equipment required for spinning the fibers is designed at Fraunhofer ISC to meet application and specific customer requirements. The shape and size of the fiber fleeces can also be adjusted to customer specifications.

Wounds only heal quickly and effectively if the wounded tissue is sufficiently supplied with nutrients. At the same time, metabolic products have to be removed. In contrast to many products on the market that allow nutrient transport only after biodegradation has started, the open-meshed Renacer® membrane promotes this transport directly after implantation, while not allowing cell passage.

Membrane with an inorganic character
There is another advantage: The Renacer® membrane dissolves completely into almost pH neutral non-toxic ortho-silicic acid, the only water-soluble form of silica. It is physiologically present in the body and has been shown to stimulate connective skin tissue formation and bone formation. Products currently available do not exhibit such bioactive properties. Many biodegradable materials dissolve into organic acids, such as lactic acid or glycolic acid. This can cause local acidification in the tissue, which then triggers inflammatory reactions of the immune system. “Our tests have shown that the dissolution product, ortho-silicic acid, is also non-toxic and completely biocompatible with cells,” says Ziemann. “The membrane decomposes into a single molecule – ortho-silicic acid.”

Fibers as a depot for active substances
Furthermore, drugs can be encapsulated into the matrix of the silica gel fibers, to be released during material resorption. “For example, antibiotics could be delivered into a wound after applying a drug-loaded Renacer® membrane to prevent the formation of bacterial colonies,” elaborates Christ. At Fraunhofer ISC, the BMBF-funded GlioGel project is testing whether the Renacer® material platform can be used as a depot for active substances in the treatment of brain tumors.

Source:

Fraunhofer-Institut für Silicatforschung ISC

Image: Gaharwar Laboratory
13.12.2022

New inks for 3D-printable wearable bioelectronics

Flexible electronics have enabled the design of sensors, actuators, microfluidics and electronics on flexible, conformal and/or stretchable sublayers for wearable, implantable or ingestible applications. However, these devices have very different mechanical and biological properties when compared to human tissue and thus cannot be integrated with the human body.

A team of researchers at Texas A&M University has developed a new class of biomaterial inks that mimic native characteristics of highly conductive human tissue, much like skin, which are essential for the ink to be used in 3D printing.

This biomaterial ink leverages a new class of 2D nanomaterials known as molybdenum disulfide (MoS2). The thin-layered structure of MoS2 contains defect centers to make it chemically active and, combined with modified gelatin to obtain a flexible hydrogel, comparable to the structure of Jell-O.

Flexible electronics have enabled the design of sensors, actuators, microfluidics and electronics on flexible, conformal and/or stretchable sublayers for wearable, implantable or ingestible applications. However, these devices have very different mechanical and biological properties when compared to human tissue and thus cannot be integrated with the human body.

A team of researchers at Texas A&M University has developed a new class of biomaterial inks that mimic native characteristics of highly conductive human tissue, much like skin, which are essential for the ink to be used in 3D printing.

This biomaterial ink leverages a new class of 2D nanomaterials known as molybdenum disulfide (MoS2). The thin-layered structure of MoS2 contains defect centers to make it chemically active and, combined with modified gelatin to obtain a flexible hydrogel, comparable to the structure of Jell-O.

“The impact of this work is far-reaching in 3D printing,” said Dr. Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering and Presidential Impact Fellow. “This newly designed hydrogel ink is highly biocompatible and electrically conductive, paving the way for the next generation of wearable and implantable bioelectronics.”1 

The ink has shear-thinning properties that decrease in viscosity as force increases, so it is solid inside the tube but flows more like a liquid when squeezed, similar to ketchup or toothpaste. The team incorporated these electrically conductive nanomaterials within a modified gelatin to make a hydrogel ink with characteristics that are essential for designing ink conducive to 3D printing.

“These 3D-printed devices are extremely elastomeric and can be compressed, bent or twisted without breaking,” said Kaivalya Deo, graduate student in the biomedical engineering department and lead author of the paper. “In addition, these devices are electronically active, enabling them to monitor dynamic human motion and paving the way for continuous motion monitoring.”

In order to 3D print the ink, researchers in the Gaharwar Laboratory designed a cost-effective, open-source, multi-head 3D bioprinter that is fully functional and customizable, running on open-source tools and freeware. This also allows any researcher to build 3D bioprinters tailored to fit their own research needs.

The electrically conductive 3D-printed hydrogel ink can create complex 3D circuits and is not limited to planar designs, allowing researchers to make customizable bioelectronics tailored to patient-specific requirements.

In utilizing these 3D printers, Deo was able to print electrically active and stretchable electronic devices. These devices demonstrate extraordinary strain-sensing capabilities and can be used for engineering customizable monitoring systems. This also opens up new possibilities for designing stretchable sensors with integrated microelectronic components.

One of the potential applications of the new ink is in 3D printing electronic tattoos for patients with Parkinson’s disease. Researchers envision that this printed e-tattoo can monitor a patient’s movement, including tremors.

This project is in collaboration with Dr. Anthony Guiseppi-Elie, vice president of academic affairs and workforce development at Tri-County Technical College in South Carolina, and Dr. Limei Tian, assistant professor of biomedical engineering at Texas A&M.
This study was funded by the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Neurological Disorders and Stroke and the Texas A&M University President’s Excellence Fund. A provisional patent on this technology has been filed in association with the Texas A&M Engineering Experiment Station.

1 This study was published in ACS Nano.

Source:

Alleynah Veatch Cofas, Texas A & M University

Photo: Marlies Thurnheer
25.10.2022

Textile Electrodes for Medtech Applications

  • Successful financing round for Empa spin-off Nahtlos

Nahtlos, an Empa spin-off, has received 1 million Swiss francs in a first round of financing from a network of business angels from Switzerland and Liechtenstein and from the Startfeld Foundation. With this funding, Nahtlos aims to drive the market entry of its newly developed textile-based electrode for medical applications.

  • Successful financing round for Empa spin-off Nahtlos

Nahtlos, an Empa spin-off, has received 1 million Swiss francs in a first round of financing from a network of business angels from Switzerland and Liechtenstein and from the Startfeld Foundation. With this funding, Nahtlos aims to drive the market entry of its newly developed textile-based electrode for medical applications.

Over the past two years, Nahtlos, an Empa spin-off, has developed novel textile-based electrodes for recording heart activity (electrocardiogram, ECG) – for example, to detect atrial fibrillation – and for electrostimulation therapies, for example, to preserve the muscle mass in paralyzed patients. Textile-based electrodes enable gentle and skin-friendly application, even if the electrodes have to be worn for several days or even weeks. The textile electrode is thus the first alternative to the gel electrode, which was developed 60 years ago and is still considered the standard for medical applications today.

Nahtlos founder and former Empa researcher Michel Schmid and co-founder and business economist José Näf have further developed the textile-based technology, which was developed and patented at Empa in various projects funded by Innosuisse, among others. The goal was to produce a product for long-term medical applications that reliably records ECG signals for up to several weeks, achieves a high level of patient acceptance and is cost-effective for the healthcare provider. Today, the patent for textile-based electrode technology is owned by Nahtlos after reaching a milestone.

Financing by business angels and Startfeld Foundation
Schmid and Näf were looking for investors to certify their product, set up production and develop the market – and recently found what they were looking for: In a seed financing round, the two young entrepreneurs were able to acquire 1 million Swiss francs from business angels from Switzerland and Liechtenstein as well as from the Startfeld Foundation. Nahtlos was supported in setting up its company by Startfeld, the start-up promotion arm of Switzerland Innovation Park Ost (SIP Ost), in the form of coaching, consulting and early-stage financing. Nahtlos is also based in the Innovation Park Ost, where innovations are initiated and accelerated through collaboration between start-ups, companies, universities and research institutions.

Together with Empa and Nahtlos, SIP Ost was present at OLMA this year. Visitors could learn live and on the spot about Empa's research activities in the field of Digital Health as well as about the Nahtlos technology and its textile electrodes for health monitoring.

Graphik: Pixabay
11.01.2022

FIMATEC innovation network enters second funding phase

The network for the development of fiber materials technology for healthcare and sports will receive funding from the Central Innovation Programme for SMEs (ZIM) for another two years.

The Federal Ministry for Economic Affairs and Climate Action (BMWi) approved a corresponding application in December 2021. This will continue to provide funding for the development of innovative functional fibers, smart textiles and application-optimized fiber composite materials until June 2023 and strengthen the technological competitiveness and innovative strength of small and medium-sized enterprises (SMEs).

The network for the development of fiber materials technology for healthcare and sports will receive funding from the Central Innovation Programme for SMEs (ZIM) for another two years.

The Federal Ministry for Economic Affairs and Climate Action (BMWi) approved a corresponding application in December 2021. This will continue to provide funding for the development of innovative functional fibers, smart textiles and application-optimized fiber composite materials until June 2023 and strengthen the technological competitiveness and innovative strength of small and medium-sized enterprises (SMEs).

For this purpose, the FIMATEC innovation network combines competences from different engineering and scientific disciplines with small and medium-sized manufacturers and service providers from the target sectors in medicine and sports (e.g. orthopaedics, prosthetics, surgery, smart textiles) as well as players from the textile and plastics industry.      

This interdisciplinary combination of industrial partners and application-oriented research institutions increases competitiveness and enables the players to realise their technical research and development projects quickly and in a targeted manner. The focus for the joint R&D projects of the companies and research institutions is on the development of innovative materials and efficient manufacturing technologies. 
          
Fiber-based materials have become indispensable in many applications in medicine and sports. As a pure fiber, processed into a textile or as a fiber composite plastic, they offer an almost unlimited variety for adjusting property and functional profiles. At the same time, the demands on the range of functions, performance and cost-effectiveness are constantly increasing, so that there is great potential for innovation. Developments are driven on the one hand by new materials and manufacturing processes, and on the other by innovative applications. Products with new and superior functions create a technological advantage over international competitors and enable higher sales revenues. In addition, efficient processes, application-optimized materials or even the integration of functions into the basic structure of textile materials lead to lower production costs and improved marketing opportunities in the future.
For developments in this context, the partners have joined forces in the FIMATEC innovation network, thus combining their expertise. Within the network, innovative materials and processes are being developed jointly in the following areas and tested in future-oriented products and services:

  • Functional fibers
    Innovative fiber materials with integrated functionalities
  • Preforming
    Highly load path optimized fiber orientations for complex fiber composite components.    
  • Smart Textiles
    Textile-based sensors and actuators
  • Hybrid material and manufacturing technologies
    Application-optimized components through cross-technology solution approaches.    
  • Fiber composites  
    Intelligent matrix systems and function-optimized fiber materials.    
  • Fiber-reinforced 3D printing  
    High-quality additive manufacturing processes for the efficient production of individualized products.

 
17 network partners are researching fiber-based materials for medical and sports technologyCurrently, ten companies and seven research institutions are involved in FIMATEC. Interested companies and research institutions as well as potential users can continue to participate in the cooperation network or R&D projects. In the course of membership, the partners are actively supported in identifying and initiating innovation projects as well as securing financing through funding acquisition. One application for ZIM project funding has already been approved by FIMATEC in its first year.

The aim of the already approved project "CFKadapt" is to develop a thermoformable fiber-plastic composite material for optimally adaptable orthopedic aids such as prostheses and orthoses. In the "Modul3Rad" project, which is currently being worked out in detail, the project partners intend to develop a modular lightweight frame system for the construction of user-friendly therapy tricycles, suitable for everyday use by severely and very severely disabled children. Three further collaborative projects are already in the planning stage.

The technology and knowledge transfer enables in particular small and medium-sized enterprises (SMEs) to access cutting-edge technological research, especially these are often denied access to innovations due to the lack of their own research departments. The IWS GmbH has taken over the network management for FIMATEC and supports the partners from the first idea to the search for suitable project partners and the preparation and coordination of funding applications. The aim is to obtain funding from the Central Innovation Programme for SMEs (ZIM), which offers companies funding opportunities for a wide range of technical innovation projects in cooperation with research institutions.

FIMATEC-netzwork partners
all ahead composites GmbH | Veitshöchheim | www.bike-ahead-composites.de
Altropol Kunststoff GmbH | Stockelsdorf | www.altropol.de
Diondo GmbH | Hattingen | www.diondo.com
Mailinger innovative fiber solutions GmbH | Sontra | www.mailinger.de
Sanitätshaus Manfred Klein GmbH & Co. KG | Stade | www.klein-sanitaetshaus.de
STREHL GmbH & Co KG | Bremervörde | www.rehastrehl.de
WESOM Textil GmbH | Olbersdorf | www.wesom-textil.de
Faserinstitut Bremen e.V. (FIBRE) | www.faserinstitut.de
E.F.M. GmbH | Olbersdorf | www.efm-gmbh.de
REHA-OT Lüneburg Melchior und Fittkau GmbH | Olbersdorf | www.rehaot.de
Fraunhofer-Institut für Fertigungstechnik und Angewandte Materialforschung IFAM | Bremen | www.ifam.fraunhofer.de
Leibniz-Institut für Polymerforschung Dresden e.V. (IPF) | www.ipfdd.de
Institut für Polymertechnologien Wismar e.V. (IPT) | www.ipt-wismar.de
Institut für Verbundwerkstoffe GmbH | Kaiserslautern | www.ivw.uni-kl.de

Associated network partners
9T Labs AG | Zürich, Schweiz | www.9tlabs.com
Fachhochschule Nordwestschweiz, Institut für Kunststofftechnik (FHNW) | www.fhnw.ch
KATZ - Kunststoff Ausbildungs- und Technologie-Zentrum | Aarau, Schweiz | www.katz.ch

Source:

Textination / IWS Innovations- und Wissensstrategien GmbH

08.12.2020

Fraunhofer FEP: Boosting Innovations for COVID-19 Diagnostic, Prevention and Surveillance

The recently launched 6.1 million Euro project INNO4COV-19, funded by the European Commission (grant agreement no. 101016203), will support the marketing of new products to combat COVID-19 over the next two years, throughout Europe. The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP is contributing its know-how in sterilization using accelerated electrons and on near-to-eye visualization.

The €6.1 million project INNO4COV-19 is committed to supporting the commercialization of new products across Europe for combatting COVID-19 over the next two years. Looking for the fast development of products – from medical technologies to surveillance solutions - the project will boost innovation to tackle the new coronavirus, reinforcing Europe's technological leadership, and invigorating an industrial sector capable of protecting citizens' safety and well-being.

The recently launched 6.1 million Euro project INNO4COV-19, funded by the European Commission (grant agreement no. 101016203), will support the marketing of new products to combat COVID-19 over the next two years, throughout Europe. The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP is contributing its know-how in sterilization using accelerated electrons and on near-to-eye visualization.

The €6.1 million project INNO4COV-19 is committed to supporting the commercialization of new products across Europe for combatting COVID-19 over the next two years. Looking for the fast development of products – from medical technologies to surveillance solutions - the project will boost innovation to tackle the new coronavirus, reinforcing Europe's technological leadership, and invigorating an industrial sector capable of protecting citizens' safety and well-being.

Officially starting on October 1, the virtual kick-off took place on October 6 – 7, counting with the support of two European Commission officers.

The 11-partner consortium led by INL – International Iberian Nanotechnology Laboratory, is looking for efficient and fast solutions that can help in the fight against COVID-19 jointly with the other actively involved industrial and RTO partners.

The mission of INNO4COV-19 is to create a “lab-to-fab” platform and a collaboration resource where companies and reference laboratories will find the tools for developing and implementing innovative technologies – from idea assessment to market exploitation. This work will be carried out as part the European Union Coronavirus initiative and in strong collaboration with all the funded projects where to accelerate the time to market for any promising product.

INNO4COV-19 is set to assist up to 30 test cases and applications from several areas spanning from Medical technologies, Environmental Surveillance systems, Sensors, Protection of Healthcare workers and Artificial Intelligence and Data mining. To achieve this, INNO4COV-19 is awarding half of the budget to support 30 enterprises selected through a set number of open calls during the first year of the project.

The first call will be launched in November 2020 across several platforms. Awardees will receive up to €100,000 each and benefit from the INNO4COV-19 consortium's technical, regulatory, and business expertise.

Roll-to-Roll Equipment and Electron Beam Technology for Large Area Sterilization of textile materials
During pandemic events like COVID-19, MERS, SARS or Ebola a substantial shortage of sterile materials for medical uses was observed due to peak demands. Fraunhofer FEP will contribute their roll-to-roll equipment and electron beam technology for the purpose of large area sterilization of textile materials to the INNO4COV-19 project.

Usually the textile material is produced in non-sterile conditions and therefore must be sterilized before being delivered to the consumers (e. g. hospitals); Sterilization at product level (sterilizing the final manufactured masks) is limited in throughput, due to a high number of individual small pieces, that must be sterilized.

Project manager Dr. Steffen Günther of Fraunhofer FEP explains the role and aims of the institute in more detail: “INNO4COV-19 will establish and verify a process chain for high throughput (4500 m²/h) electron beam sterilization of fabric material in roll-form in a single TRL 7 pilot machine to allow efficient manufacturing of sterile face masks and other fabric based sterile products without the need to sterilize the final product.”

OLED Microdisplays for Detecting Infected People
Another topic of Fraunhofer FEP within INNO4COV-19 deals with the earliest possible detection of infected people. A widely used strategy to early identify individuals with disease symptoms is body temperature screening using thermal cameras.

One possibility to allow continuous body temperature monitoring, is the integration of a thermal camera into a smart wearable device. Therefore, Fraunhofer FEP is using their OLED microdisplay technology. This allows small (< 3 × 2 cm²), ultrathin (< 5 mm including control circuitry) and ultra-low power (< 5 mW) devices to show visual information. In combination with an infrared sensor a thermal imager will be realized to both measure body temperature and directly displays the result via near-to-eye visualization. The system can be embedded within smart glasses, hats, caps or personal face shields.

About INNO4COV-19 project:
Website: www.inno4cov19.eu
Please contact: info@inno4cov19.eu

 

Source:

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP